Glenmark Pharmaceuticals S.A.
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
Recorded as renamed to Ichnos Sciences S.A. (2020)
2
Ending by 2030
Jan 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Novel Compounds as Ror Gamma Modulators (US 10,344,024) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due May 17, 2027The maintenance fee for Treatment of respiratory disorders using TRPA1 antagonists (US 9,186,360) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Nanoparticulate formulation comprising a TRPA1 antagonist (US 10,603,277) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,119,647 | Fused pyrimidineone compounds as TRPV3 modulators In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,278 | Thienopyrimidinedione Derivatives as TRPA1 Modulators In force · Low confidence | In force | Low confidence | |
| US D823,460 | Anal device In force · From the USPTO record | In force | From the USPTO record | |
| US 9,186,360 | Treatment of respiratory disorders using TRPA1 antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 10,603,277 | Nanoparticulate formulation comprising a TRPA1 antagonist In force · From the USPTO record | In force | From the USPTO record | |
| US 10,344,024 | Novel Compounds as Ror Gamma Modulators In force · High confidence | In force | High confidence | |
| US 7,943,634 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors In force Term ended Nov 13, 2026 · From the USPTO record | In force | Term ended Nov 13, 2026 | From the USPTO record |
Also on record, not counted in the 7: 13 patents in force now held by others · 51 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned · 50 no status recorded